←
Connor Kinslow, MD1,146 posts
Connor Kinslow, MD avatar✓

Connor Kinslow, MD ✓

@RadOncConnor

Passion for cancer research and clinical oncology. Radiation Oncology at MSKCC. #CancerOutcomes #NeuroOnc #CancerMetabolism

◷ Joined April 2020▧ 138 Photos and videos
Connor Kinslow, MD avatar
Connor Kinslow, MD@RadOncConnor·Oct 21

7/n Age >40 is a surrogate for IDH in g 2-3 glioma, but is not prognostic in IDH-mut glioma or predictive of benefit from CRT. Age >40 in isolation should not be an indication for adjuvant therapy. Guidelines should be updated to reflect contemporary prognostic factors.

Connor Kinslow, MD avatar
Connor Kinslow, MD@RadOncConnor·Oct 21

6/n Pooling RCTs of CRT vs RT for grade 2-3 IDH-mutant glioma, age >40 was not predictive of benefit from CRT over RT alone.

Post attachment
Connor Kinslow, MD avatar
Connor Kinslow, MD@RadOncConnor·Oct 21

5/n Features of "molecular GBM" were more common in IDH-wt tumors in patients >40 YO, in-part explaining the prognostic significance in this subgroup.

Post attachment
Connor Kinslow, MD avatar
Connor Kinslow, MD@RadOncConnor·Oct 21

3/n Age >40 was not prognostic in IDH-mutant glioma, but was prognostic in IDH-mutant lower grade glioma (interaction <.001).

Post attachment
Connor Kinslow, MD avatar
Connor Kinslow, MD@RadOncConnor·Oct 21

2/n We determined if age is prognostic/predictive in grade 2-3 gliomas or merely a surrogate for IDH status. We evaluated almost 3,000 patients, many from major cooperative group trials. Age predicted IDH status (95% vs. 62% IDH-mutant over/under 40 YO).

Post attachment
Connor Kinslow, MD avatar
Connor Kinslow, MD@RadOncConnor·Oct 21

1/n Virtually every RCT of CRT for LGG used age ≥40 yrs as inclusion. Every major guidelines still cites age as a high-risk factor for LGG

Post attachmentPost attachment
Abhishek A. Solanki, MD MS avatar
⟳ Connor Kinslow, MD retweeted
Abhishek A. Solanki, MD MS@abhiAsolanki·Oct 15

1/6: I am excited to share our multi-institutional F-SHARP phase I/II trial, now published in @JCO_ASCO! doi.org/10.1200/JCO-25-02730 There are limited prospective data defining the optimal management of intraprostatic radiorecurrence (IPR) after definitive RT for prostate cancer. We asked: 1. Is dose-escalated focal salvage high dose rate brachytherapy safe and effective for IPR? 2. Can Decipher (@Veracyte) identify patients with higher risk of recurrence with salvage ReRT that may benefit from therapeutic intensification? 🧵👇

Ramon Sun avatar
⟳ Connor Kinslow, MD retweeted
Ramon Sun@RCSunlab·Jun 9

Excited to share our new paper out today in @NatureMetabolism! "Hyperglycosylation is a metabolic driver of Alzheimer’s disease" *We bridged spatial metabolomics (MALDI-MSI glycomics + lipidomics + isotopic pulse-chase tracing) directly to experimental biochemistry (genetic knockdown of glycan enzymes + glucosamine supplementation in AD models) and real-world public health data (EHR analysis showing glucosamine use linked to faster MCI-to-AD progression and worse survival). **Key takeaway: The AD brain shows conserved hyperglycosylation driven by ramped-up glycan biosynthesis — not just a byproduct, but a causal driver. Reducing it helps cognition; boosting it (e.g., via glucosamine) worsens outcomes. ***We applied cutting-edge spatial tech to functional validation and clinical translation. Full open-access paper: nature.com/articles/s42255-0… Huge thanks to the incredible team, collaborators (incl. Matt Gentry, Stefan Prokop, @ji0ngbi0n , Yi Guo, @lichenbiostat, Ralph Deberardinis & others), and the patients/families who make this work possible.

Ramon Sun avatar
⟳ Connor Kinslow, MD retweeted
Ramon Sun@RCSunlab·Oct 1

Halloween is in full swing, follow our journey every year as well try to out do ourselves each year on decoration !!

Post attachmentPost attachment
0:21